)
Visual
test
EBOS Group
EBOS Group (EBO) investor relations material
EBOS Group AGM 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2025 summary29 Oct, 2025
Opening remarks and agenda
Chair welcomed attendees in person and online, introduced directors, CEO, and CFO, and explained meeting logistics and structure, including year highlights, financial review, and formal business with four resolutions.
Financial performance review
FY25 underlying revenue grew 12% to NZD 12.3 billion, with underlying EBITDA up 7.5% to NZD 585 million, in line with guidance and supported by organic growth and new customer wins.
Statutory EPS declined 22.4% to 109.7 cps, with underlying EPS at 131.3 cps, mainly due to the loss of the Chemist Warehouse contract.
Full-year dividend maintained at NZD 118.5 cps, payout ratio 83.8%, consistent with FY24.
Net profit after tax was NZD 250 million on NZD 23.2 billion turnover, with margin pressure from high-cost medicines and competitive wholesale market.
Growth objectives for FY25 were met, with strategic investments in distribution and acquisitions.
Board and executive committee updates
CEO transition from John Cullity to Adam Hall, who commenced on 1 July 2025 after a global search for strategic and operational expertise.
Coline McConville appointed as Non-Executive Director, bringing international governance and M&A experience.
Board renewal ongoing, with five new directors since July 2021; six of seven are independent.
Mitigation of Chemist Warehouse contract loss
DC renewal program's impact on ROCE and CapEx
Strategy for improving margins in pharmacy/animal care?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebJ
Strong growth, digital innovation, and margin expansion drive robust multi-year financial outlook. - 6 Feb004020
Operating profit rose on cost savings and high-value sales, with major US expansion underway. - 6 FebJOUT
Net sales up 31%, gross margin at 36.6%, and net loss narrowed to $3.3 million. - 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
Next EBOS Group earnings date
H1 202624 Feb, 2026
EBOS Group
Next EBOS Group earnings date
H1 202624 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
EBOS Group Limited is a healthcare and animal care company involved in the distribution, marketing, and wholesaling of medical, pharmaceutical, and veterinary products. The company supplies a broad range of products and services, including pharmaceuticals, medical consumables, and equipment to hospitals, pharmacies, and healthcare providers. Additionally, EBOS operates in the animal care sector, offering pet food, healthcare products, and veterinary services. The company emphasizes operational efficiency and quality in its distribution network, supporting healthcare and veterinary sectors in Australia and New Zealand. The company is headquartered in Christchurch, New Zealand, and its shares are listed on the NZX and ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage